+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5559833
Cervical Cancer Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global cervical cancer drugs market as it emerges from the Covid 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the cervical cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cervical Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Cancer Type: Squamous Cell Cancer; Adenocarcinoma
2) By Drug Type: Avastin; Bevacizumb; Blemocin; Blenoxane; Others
3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Others

Companies Mentioned: F.Hoffmann-La Roche Ltd.; Hetero; GlaxoSmithKline; Eli Lilly and Company; Pfizer

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Cervical Cancer Drugs Market

What is the estimated value of the Global Cervical Cancer Drugs Market?

The Global Cervical Cancer Drugs Market was estimated to be valued at $23.23 billion in 2022.

What is the growth rate of the Global Cervical Cancer Drugs Market?

The growth rate of the Global Cervical Cancer Drugs Market is 7.4%, with an estimated value of $30.95 billion by 2026.

What is the forecasted size of the Global Cervical Cancer Drugs Market?

The Global Cervical Cancer Drugs Market is estimated to be worth $30.95 billion by 2026.

Who are the key companies in the Global Cervical Cancer Drugs Market?

Key companies in the Global Cervical Cancer Drugs Market include F.Hoffmann, La Roche Ltd., Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Alnylam Pharmaceuticals, Allergan plc. and Bristol.

Table of Contents

1. Executive Summary2. Cervical Cancer Drugs Market Characteristics3. Cervical Cancer Drugs Market Trends And Strategies4. Impact Of COVID-19 On Cervical Cancer Drugs
5. Cervical Cancer Drugs Market Size And Growth
5.1. Global Cervical Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Cervical Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Cervical Cancer Drugs Market Segmentation
6.1. Global Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Squamous Cell Cancer
  • Adenocarcinoma
6.2. Global Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Avastin
  • Bevacizumb
  • Blemocin
  • Blenoxane
  • Others
6.3. Global Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

7. Cervical Cancer Drugs Market Regional And Country Analysis
7.1. Global Cervical Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Cervical Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Cervical Cancer Drugs Market
8.1. Asia-Pacific Cervical Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.4. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Cervical Cancer Drugs Market
9.1. China Cervical Cancer Drugs Market Overview
9.2. China Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.4. China Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Cervical Cancer Drugs Market
10.1. India Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.3. India Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Cervical Cancer Drugs Market
11.1. Japan Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.3. Japan Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Cervical Cancer Drugs Market
12.1. Australia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.3. Australia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Cervical Cancer Drugs Market
13.1. Indonesia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.3. Indonesia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Cervical Cancer Drugs Market
14.1. South Korea Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.3. South Korea Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Cervical Cancer Drugs Market
15.1. Western Europe Cervical Cancer Drugs Market Overview
15.2. Western Europe Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.4. Western Europe Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Cervical Cancer Drugs Market
16.1. UK Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.3. UK Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Cervical Cancer Drugs Market
17.1. Germany Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.3. Germany Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Cervical Cancer Drugs Market
18.5. France Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.6. France Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.7. France Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Cervical Cancer Drugs Market
19.1. Eastern Europe Cervical Cancer Drugs Market Overview
19.2. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.4. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Cervical Cancer Drugs Market
20.1. Russia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.3. Russia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Cervical Cancer Drugs Market
21.1. North America Cervical Cancer Drugs Market Overview
21.2. North America Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.4. North America Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Cervical Cancer Drugs Market
22.1. USA Cervical Cancer Drugs Market Overview
22.2. USA Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.4. USA Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Cervical Cancer Drugs Market
23.1. South America Cervical Cancer Drugs Market Overview
23.2. South America Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.4. South America Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Cervical Cancer Drugs Market
24.1. Brazil Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.3. Brazil Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Cervical Cancer Drugs Market
25.1. Middle East Cervical Cancer Drugs Market Overview
25.2. Middle East Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.4. Middle East Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Cervical Cancer Drugs Market
26.1. Africa Cervical Cancer Drugs Market Overview
26.2. Africa Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.4. Africa Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Cervical Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Cervical Cancer Drugs Market Competitive Landscape
27.2. Cervical Cancer Drugs Market Company Profiles
27.2.1. F. Hoffmann-La Roche Ltd
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Hetero
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. GlaxoSmithKline
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Eli Lilly and Company
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Pfizer
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Cervical Cancer Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Cervical Cancer Drugs Market30. Cervical Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the cervical cancer drugs market are F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Alnylam Pharmaceuticals, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company and Novartis AG.

The global cervical cancer drugs market is expected to grow from $21.29 billion in 2021 to $23.23 billion in 2022 at a compound annual growth rate (CAGR) of 2.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $30.95 billion in 2026 at a CAGR of 7.4%.

The cervical cancer drugs market consists of sales of cervical cancer drugs used for the treatment of cervical cancer in women. The cervical cancer is the medical condition in which there is a tumor formation in the lower portion of uterus which is known as cervix.

The main types of cancer in cervical cancer drugs are squamous cell cancer and adenocarcinoma. Squamous cell carcinoma (SCC) is a kind of skin cancer which starts in the squamous cells. The epidermis, or outermost layer of the skin, is made up of thin, flat cells called squamous cells. The different types of drugs include avastin, bevacizumb, blemocin, blenoxane, others and distributed through various channels such as hospitals pharmacies, retail pharmacies, others.

North America is the largest region in the cervical cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally, HIV weakens the immune system which increases the likelihood of cervical cancer. Women with HIV have an increased chance of being diagnosed with cervical cancer because the count of the protein CD4 goes down. According to a survey conducted by the National cancer institute, a person with HIV is three time as likely to be diagnosed with cervical cancer.

The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market. A lot of cervical cancer-related deaths among women are due to late diagnosis of disease. The lack of awareness leads to avoidance about the disease; this ignorance causes delayed diagnosis and medication/treatment. According to, a study conducted at the Bowen University Teaching Hospital (BUTH), in Nigeria, about 318 women from the general outpatient clinic were interviewed to assess the level of awareness of cervical cancer. The level of awareness for cervical cancer was 22.6% and 17.9% for screening tests, with major sources of information being from health talks and hospital staffs.

The cervical cancer drugs market is experiencing a number of significant trends that helps in efficient and targeted treatment of the disease including advances in drug delivery. One such trend is the use of drugs that can be delivered directly from the vagina such as drugs using vaginal formulations as gels, creams, pessaries, rings, films and tablets. These drugs ease the localized treatment of cervical cancer. The formulation of these drugs is in such a way that they get easily absorbed into vaginal tissue and reach the site of action. For instance, companies introduced vaginal gels such as Cidofovir gel and 851B Gel into the market to treat cervical cancer. As per the reports by International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)'s Clinical Trials Registry, 851B Gel is in trial phase. Whereas Cidofovir gel, sold under the brand name Vistide, is already a success in the market. In addition to the above-mentioned gels, drugs such as ISA101, AGEN2034 and Z-100 are in pipeline and promise growth to the cervical cancer drugs market.

The U.S. Food And Drug Administration (FDA) regulates the safety and effectiveness of cancer drugs in the market. The Oncologic Drugs Advisory Committee process evaluation and clinical trials of cancer drugs requested by FDA. The Division of Oncology Products 1 (DOP1) regulates investigation, application, licensing of new drug for gynecological cancers. Various clinical trials are done for approval of cervical cancer drugs. Under the title 21CFR314, subpart H regulates the approval of new drugs that are for serious illness.

In January 2019, Bristol-Myers Squibb, an American biopharmaceutical company acquired Celgene for $74 billion. This acquisition will enable the Bristol-Myers Squibb to hold a strong position in oncology, immunology and inflammation and cardiovascular diseases drugs market. Celgene is an American biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases globally.

The countries covered in the cervical cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • F.Hoffmann-La Roche Ltd.
  • Hetero
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Pfizer
  • Alnylam Pharmaceuticals
  • Allergan plc.
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Novartis AG
  • AstraZeneca plc.
  • Celgene
  • Merck & Co.
  • Amgen

Methodology

Loading
LOADING...